OUTLOOK 2013 â RAISING BUY LIMIT AND TARGET PRICE Over the past decade, Alkermes has evolved into a fully integrated company as they receive revenue from five ALKS-developed approved drugs and have established a real R&D pipeline. ALKS has emerged as a leader in the development of injectable antipsychotics that can be administered as infrequently[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.